Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioAtla (BCAB) Gains from Investment Securities (2020 - 2025)

BioAtla (BCAB) has disclosed Gains from Investment Securities for 6 consecutive years, with -$721000.0 as the latest value for Q4 2025.

  • For Q4 2025, Gains from Investment Securities changed N/A year-over-year to -$721000.0; the TTM value through Dec 2025 reached -$730000.0, down 8011.11%, while the annual FY2025 figure was $9000.0, 99.85% down from the prior year.
  • Gains from Investment Securities hit -$721000.0 in Q4 2025 for BioAtla, down from $5.9 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $6.3 million in Q1 2024 and bottomed at -$721000.0 in Q4 2025.
  • Average Gains from Investment Securities over 5 years is $2.0 million, with a median of $601596.0 recorded in 2021.
  • On a YoY basis, Gains from Investment Securities climbed as much as 21727.14% in 2024 and fell as far as 98.47% in 2024.
  • BioAtla's Gains from Investment Securities stood at $353043.0 in 2021, then plummeted by 101.98% to -$7000.0 in 2022, then surged by 71.43% to -$2000.0 in 2023, then surged by 3174.4% to $61488.0 in 2024, then crashed by 1272.59% to -$721000.0 in 2025.
  • According to Business Quant data, Gains from Investment Securities over the past three periods came in at -$721000.0, $5.9 million, and $149159.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.